DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Condition: Small Cell Lung Cancer · Large Cell Neuroendocrine Lung Carcinoma · Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology · Sponsor: Boehringer Ingelheim
About this study
This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310. The purpose of Part 2 is to see how obrixtamig and ZL-1310 is tolerated when given with another medicine called a checkpoint inhibitor. Another purpose is to check whether the study treatment can stop the cancer from growing and keep it stable. Obrixtamig and ZL-1310 are being developed to help the immune system fight cancer. In Part 1, participants get obrixtamig and ZL-1310. In Part 2, participants get obrixtamig and ZL-1310 with a checkpoint inhibitor. Part 2 is only open to people with advanced small cell lung cancer. All study treatments are given as infusions into a vein. The study does not have a fixed duration. Participants can receive study treatment for up to 2 years if they benefit from treatment and can tolerate it. Participants visit the study site regularly, with some overnight stays required. During this time, doctors regularly check for health problems that could be caused by the study treatment. They also monitor the size of the tumour(s) and take laboratory tests.
This description comes directly from the study's public registry record.
Talk to the study team
Boehringer Ingelheim · 1-800-243-0127 · clintriage.rdg@boehringer-ingelheim.com
Always discuss trial participation with your own doctor first.
Locations (26)
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| University of Kentucky Medical Center | Lexington, Kentucky, United States | — |
| Chris Obrien Lifehouse | Camperdown, New South Wales, Australia | — |
| Universitair Ziekenhuis Antwerpen | Edegem, Belgium | — |
| Universitair Ziekenhuis Gent | Ghent, Belgium | — |
| The Affiliated Cancer Hospital, Guangxi Medical University | Nanning, China | — |
| Shanghai Chest Hospital | Shanghai, China | — |
| Shanghai Pulmonary Hospital | Shanghai, China | — |
| CTR Leon Berard | Lyon, France | — |
| HOP Timone | Marseille, France | — |
| Institut Gustave Roussy | Villejuif, France | — |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Mainz, Germany | — |
+ 14 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07707895